Corcept Therapeutics Inc
CORT37.500USD
+0.970+2.66%
終値 01/09, 16:00（ET）15分遅れの株価
3.94B時価総額
36.71直近12ヶ月PER
詳細情報 Corcept Therapeutics Inc 企業名
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Corcept Therapeutics Incの企業情報
企業コードCORT
会社名Corcept Therapeutics Inc
上場日Apr 15, 2004
最高経営責任者「CEO」Belanoff (Joseph K)
従業員数500
証券種類Ordinary Share
決算期末Apr 15
本社所在地101 Redwood Shores Parkway
都市REDWOOD CITY
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94065
電話番号16506888803
ウェブサイトhttps://www.corcept.com/
企業コードCORT
上場日Apr 15, 2004
最高経営責任者「CEO」Belanoff (Joseph K)
Corcept Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
--
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+129142.00%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+64824.00%
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
101.05K
+65016.00%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.87K
+275.00%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.56K
+238.00%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.52K
+246.00%
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
2.02K
-3265.00%
Mr. George Leonard Baker, Jr.
Mr. George Leonard Baker, Jr.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
--
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+129142.00%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+64824.00%
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
101.05K
+65016.00%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.87K
+275.00%
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.05%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
他の
62.41%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.05%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
他の
62.41%
種類
株主統計
比率
Investment Advisor
41.70%
Investment Advisor/Hedge Fund
22.82%
Individual Investor
11.70%
Hedge Fund
7.39%
Pension Fund
1.39%
Sovereign Wealth Fund
0.96%
Research Firm
0.74%
Bank and Trust
0.43%
Family Office
0.06%
他の
12.82%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
801
79.27M
75.36%
-8.80M
2025Q3
810
79.55M
83.49%
-543.84K
2025Q2
778
80.03M
86.89%
-4.55M
2025Q1
736
84.99M
89.94%
-9.90M
2024Q4
668
86.02M
93.22%
-3.95M
2024Q3
614
90.10M
96.25%
-1.26M
2024Q2
578
91.29M
99.95%
-4.43M
2024Q1
572
95.57M
89.61%
+2.81M
2023Q4
546
86.50M
88.14%
+1.82M
2023Q3
531
84.62M
88.02%
+2.14M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
10.93M
10.39%
-380.74K
-3.37%
Sep 30, 2025
The Vanguard Group, Inc.
9.51M
9.05%
-144.25K
-1.49%
Sep 30, 2025
Ingalls & Snyder LLC (Asset Management)
7.70M
7.32%
-24.94K
-0.32%
Sep 30, 2025
Renaissance Technologies LLC
6.09M
5.79%
-177.06K
-2.83%
Sep 30, 2025
Baker (George Leonard Jr.)
5.31M
5.05%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.87M
3.68%
+329.00
+0.01%
Sep 30, 2025
Belanoff (Joseph K)
2.98M
2.83%
--
--
Dec 24, 2025
State Street Investment Management (US)
2.97M
2.82%
+2.81K
+0.09%
Sep 30, 2025
Wilson (James N)
2.35M
2.23%
+129.14K
+5.82%
Apr 17, 2025
Fidelity Management & Research Company LLC
2.15M
2.04%
+789.13K
+58.16%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco S&P SmallCap Health Care ETF
4.22%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Invesco Pharmaceuticals ETF
2.82%
State Street SPDR S&P Pharmaceuticals ETF
2.67%
iShares U.S. Pharmaceuticals ETF
2.55%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.48%
Formidable ETF
2.47%
Alger Russell Innovation ETF
2.09%
Invesco S&P SmallCap 600 Pure Growth ETF
1.73%
Fidelity Stocks for Inflation ETF
1.52%
詳細を見る
Invesco S&P SmallCap Health Care ETF
比率4.22%
First Trust NYSE Arca Biotechnology Index Fund
比率3.34%
Invesco Pharmaceuticals ETF
比率2.82%
State Street SPDR S&P Pharmaceuticals ETF
比率2.67%
iShares U.S. Pharmaceuticals ETF
比率2.55%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率2.48%
Formidable ETF
比率2.47%
Alger Russell Innovation ETF
比率2.09%
Invesco S&P SmallCap 600 Pure Growth ETF
比率1.73%
Fidelity Stocks for Inflation ETF
比率1.52%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Corcept Therapeutics Incの上位5名の株主は誰ですか？
Corcept Therapeutics Incの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は10.93M株を保有しており、これは全体の10.39%に相当します。
The Vanguard Group, Inc.は9.51M株を保有しており、これは全体の9.05%に相当します。
Ingalls & Snyder LLC (Asset Management)は7.70M株を保有しており、これは全体の7.32%に相当します。
Renaissance Technologies LLCは6.09M株を保有しており、これは全体の5.79%に相当します。
Baker (George Leonard Jr.)は5.31M株を保有しており、これは全体の5.05%に相当します。
BlackRock Institutional Trust Company, N.A.は10.93M株を保有しており、これは全体の10.39%に相当します。
The Vanguard Group, Inc.は9.51M株を保有しており、これは全体の9.05%に相当します。
Ingalls & Snyder LLC (Asset Management)は7.70M株を保有しており、これは全体の7.32%に相当します。
Renaissance Technologies LLCは6.09M株を保有しており、これは全体の5.79%に相当します。
Baker (George Leonard Jr.)は5.31M株を保有しており、これは全体の5.05%に相当します。
Corcept Therapeutics Incの株主タイプ上位3種は何ですか？
Corcept Therapeutics Incの株主タイプ上位3種は、
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Ingalls & Snyder LLC (Asset Management)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Ingalls & Snyder LLC (Asset Management)
Corcept Therapeutics Inc（CORT）の株式を保有している機関の数はいくつですか？
2025Q4時点で、Corcept Therapeutics Incの株式を保有している機関は801社あり、保有株式の総市場価値は約79.27Mで、全体の75.36%を占めています。2025Q3と比較して、機関の持ち株は-8.13%増加しています。
Corcept Therapeutics Incの最大の収益源は何ですか？
--において、--部門がCorcept Therapeutics Incにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
